Harnessing Nanoparticles for Immune Modulation

Correction

Harnessing Nanoparticles for Immune Modulation Daniel R. Getts,* Lonnie D. Shea, Stephen D. Miller, and Nicholas J.C. King *Correspondence: [email protected] (D.R. Getts). DOI of Correction: http://dx.doi.org/10.1016/j.it.2015.05.007 (Trends in Immunology 36, 419–427; July 2016)

Due to an oversight in the preparation of this Review article, the authors inadvertently included a “rat” model for “Complete LAD occlusion” in Table 1. Findings on “Japanese encephalitis” were erroneously attributed to reference 8 but are unpublished observations. Table 1 was modified to reflect those changes and the corrected version is included below. That authors apologize for these errors and assert that they make no difference to the line of discussion of this review.

Table 1. IMP Efficacy in Severe Inflammation Models. Condition

Animal model

Species

Outcome

Refs

Acute myocardial infarction

Temporary LAD occlusion Complete LAD occlusion

Mouse Mouse

Reduced inflammation, reduced infarct size Increased function

[8]

Kidney ischemia

Temporary renal artery occlusion

Mouse

Reduced tubular necrosis and increased function

[8]

Stroke

Temporary carotid artery

Mouse

Reduced inflammation

Unpublished

MS relapse

EAE SJL (relapsing–remitting) EAE C57BL/6 (progressive disease)

Mouse Mouse

Reduced symptoms, reduced inflammation and demyelination

[8]

IBD

DSS colitis

Mouse

Reduced symptoms, reduced inflammation, rapid recovery of the colon

[8]

Acute encephalitis syndrome

WNV encephalitis Japanese encephalitis

Mouse Mouse

Increased survival Increased survival

[8] Unpublished

Spinal cord injury

Spinal cord crush

Mouse

Increased mobility, reduced inflammation

Unpublished

Trends in Immunology, October 2016, Vol. 37, No. 10

http://dx.doi.org/10.1016/j.it.2016.08.003

715